Sector News

Biotech buys get pharma M&A off to flying start in 2015

March 6, 2015
Life sciences
(Reuters) – AbbVie’s $21 billion deal to buy Pharmacyclics shows big pharma’s hunger for new drugs at a time when research at smaller biotechnology companies is driving some of the most promising advances in medicine.
 
Competition for tomorrow’s blockbuster drugs is now intense, inflating the cost of deals and pushing pharmaceuticals to center stage in overall mergers and acquisitions (M&A).
 
So far this year, pharma deals have accounted for 10.5 percent of total M&A worldwide, up from a more traditional share of 3 to 4 percent, according to Thomson Reuters data.
  
AbbVie’s planned purchase of Pharmacyclics is the largest global pharmaceutical deal of 2015 to date and takes M&A activity in the sector to a six-year high.
 
M&A transactions targeting biotech and pharma companies in 2015 have now reached $59.3 billion, a 94 percent increase over the same period a year ago and the highest volume for this stage in any year since 2009. For a graphic on pharma deals see link.reuters.com/tyc34w
 
Across the industry, big drugmakers are eyeing medicines developed by nimble biotech firms as they seek to replenish portfolios that are being eroded as older products face loss of patent protection.
 
Pharmacyclics gives AbbVie access to a blood cancer treatment called Imbruvica that is expected to be one of the world’s top-selling cancer drugs, reducing its reliance on the ageing rheumatoid arthritis drug Humira.
 
“This acquisition serves as a reminder that large pharma is willing to pay up for novel, quality products,” said Maxim Jacobs, an analyst at Edison Investment Research.
 
The deal also signals AbbVie Chief Executive Richard Gonzalez’s readiness to chase other assets after a failed deal to buy Shire for $55 billion last year.
 
In many ways, 2014 was the year of deals that didn’t happen. Not only did AbbVie’s plans for Shire unravel but Pfizer proved unable to land AstraZeneca after a $118 billion takeover fight.
 
Yet both U.S. predators have now bounced back with alternative deals, with Pfizer agreeing to buy Hospira, a specialist in injectable drugs, for around $15 billion last month.
 
Valeant Pharmaceuticals also agreed last month to acquire gastrointestinal drugmaker Salix Pharmaceuticals for more than $10 billion in another notable biotech transaction.
 
By Ben Hirschler (Editing by Pravin Char)

comments closed

Related News

June 3, 2023

Sanofi’s frexalimab shows early potential in in Phase II multiple sclerosis trial

Life sciences

In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.

June 3, 2023

Lonza to acquire Synaffix to strengthen ADC development

Life sciences

Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).

June 3, 2023

BD taps Novartis, GSK alum Laura Boros to lead drug delivery device business

Life sciences

In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.

How can we help you?

We're easy to reach